Lactobacillus plantarum 299v (Lp299v)
Lactobacillus plantarum 299v, aka "Lp299v", was identified in a study done at Lund University on the taxonomy of lactobacilli in the GI tract. The authors of that study then published a novel experiment that identified implantable strains of lactobacilli. Instead of testing in a lab, they tested 19 strains in vivo. Subjects ingested a variety of strains, and later biopsies of their intestinal mucosa were examined to determine which had successfully implanted1. Five of the strains persisted at least one day after administration, with Lp299v being the most dominant.
Lp299v (also known as DSM 9843), along with Lactobacillus rhamnosus 271 (DSM 6594), were patented in the USA in 1995 by the Swedish firm Probi AB (Patent number 5,474,932). The inventors were Stig Bengmark, Siv Ahrné, Göran Molin, and Bengt Jeppson, all of Sweden (most work for Probi AB). This company owns the rights to the strain, which they sell in a fresh juice product throughout Europe called "ProViva". Numerous studies have been conducted on the health benefits of Lp299v; in many it was administered in the form of ProViva.
Lp299v is available in the USA in two forms that I know of:
Who is Probi AB?
Below is an excerpt from Probi AB's newsletter explaining who they are:
I have used samples of Lp299v and experienced positive results. I support the company behind this strain (Probi AB) because of their commitment to scientific research on probiotics.
Last updated on: 2010-11-07
Disclaimer: Information on this site, including comments on medical treatments, is not intended as medical advice to visitors. It should be evaluated critically and should not take the place of medical advice from a licensed healthcare professional.